IMRA Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (23 Feb 2023 @ 16:00):

IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin...

Stats
Today's Volume	271 721
Average Volume	116 259
Market Cap	165.80M
EPS	$-0.000510 ( 2023-09-29 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	105.33
ATR14	$0.322 (5.09%)

Insider Trading

Date	Person	Action	Amount	type
2023-12-29	Lyssikatos Joseph P	Sell	12 000	Stock Option (right to buy)
2023-12-29	Lyssikatos Joseph P	Buy	12 000	Common Stock
2023-12-29	Lyssikatos Joseph P	Sell	9 151	Common Stock
2023-12-29	Lyssikatos Joseph P	Sell	2 849	Common Stock
2023-12-28	Patel Anish	Sell	2 520	Common Stock

INSIDER POWER
83.22
Last 97 transactions
Buy: 15 631 291 \| Sell: 878 871

Volume Correlation

Long: -0.10 (neutral)

Short: 0.82 (strong)

Signal:(75.335) Same movement expected

Imara Inc Correlation

10 Most Positive Correlations
BOCH	0.938
MMAC	0.916
SHSP	0.895
LMST	0.886
NETE	0.885
MNSB	0.859
SMCI	0.857
VOXX	0.844
WSC	0.841
STRL	0.84

10 Most Negative Correlations
RMRM	-0.956
TDAC	-0.93
APOP	-0.923
GAINL	-0.91
AEY	-0.888
UK	-0.878
SVOK	-0.873
FANG	-0.865
BNRG	-0.862
HUSN	-0.861

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Imara Inc Correlation - Currency/Commodity

0.66
( moderate )

0.65
( weak )

0.54
( weak )

-0.33
( neutral )

0.84
( strong )

-0.37
( neutral )

Imara Inc Financials

Annual	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$0.240

Q3	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.000500

Q2	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.000400

Q1	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$0

Financial Reports:

No articles found.

Imara Inc

IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. Its lead product candidate is IMR-687, an oral and once-a-day therapeutic that is in Phase 2b clinical trials for the treatment of sickle cell disease and ß-thalassemia. The company also develops IMR-261, an oral and clinical-ready activator of nuclear factor erythroid 2related factor 2 for the treatment of hemoglobinopathies, iron disorders, and potentially other areas. IMARA Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.